Clinical trials located in

Galdakao

Galdakao city is located in Spain. Currently, 10 clinical trials are being conducted in this city.

Galdakao, located in the province of Biscay, Spain, is a city with a rich history and cultural heritage. Nestled in the Basque Country, it is known for its unique blend of modernity and tradition. The city is home to the Hospital Galdakao-Usansolo, a key healthcare facility in the region. Galdakao also boasts the impressive Ganguren mountain, offering stunning views and outdoor activities. The city celebrates its patron saint, San Vicente, with vibrant festivities, showcasing its deep-rooted Basque customs and community spirit.

  • CT-EU-00035243

    Study on trastuzumab deruxtecan for resistant breast cancer patients

    This clinical trial, also known as the TRANSCENDER trial, is investigating the effects of a drug called Trastuzumab Deruxtecan (T-DXd) in treating a specific type of advanced breast cancer called HER2-positive. This medicine is expected to work well in people whose disease has not responded or has had an early relapse following standard treatment. The aim is to find out how effectively this drug can slow down or possibly stop the growth of cancer cells, and how safe its use is for patients. Patients in this study will receive T-DXd intravenously every 3 weeks. The dose may be adjusted if the patient’s weight changes significantly. Treatment will continue until the cancer gets worse, side effects become too severe, or the patient decides to leave the study.

    • Trastuzumab deruxtecan
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Thrombolysis therapy in treating acute Pulmonary Embolism

    This study aims to evaluate a reduced dose of thrombolytic treatment for patients with intermediate-high-risk acute pulmonary embolism. It compares the new treatment approach with a placebo to assess effectiveness and safety. The study’s focus is on reducing the risk of major and intracranial bleeding associated with full-dose thrombolytic treatment. Participants will receive either the experimental treatment or a placebo, alongside standard anticoagulation therapy. The primary goal is to determine the efficacy and safety of the reduced dosage at day 30, with long-term follow-up assessments planned. This research is crucial for improving treatment options for patients with this serious lung condition.

    • Alteplase
  • Studying effects of tozorakimab on Chronic Obstructive Pulmonary Disease (COPD)

    This clinical study evaluates the efficacy and safety of Tozorakimab in treating adults with Chronic Obstructive Pulmonary Disease (COPD) who have a history of frequent exacerbations. Participants, who must have experienced at least two moderate or one severe exacerbation in the past year, will receive tozorakimab through subcutaneous injections. The study aims to reduce the rate of COPD exacerbations over a one-year period. Participants will continue their usual inhaled lung therapies alongside the trial treatments.

    • Tozorakimab
  • Breast cancer treatment study: camizestrant vs. standard therapy

    This study is looking at a new drug called camizestrant for adults with a certain type of early breast cancer (ER+/HER2-). It compares camizestrant with standard endocrine therapies like tamoxifen and aromatase inhibitors in patients who have already received 2–5 years of endocrine therapy. The study’s focus is on preventing cancer recurrence over 60 months. About 4300 participants are involved, and the trial features an open-label design, meaning everyone knows which treatment they are receiving. The main goal is to check how well the camizestrant works in comparison to standard treatments.

    • camizestrant
    • Anastrozole
    • Letrozole
    • Exemestane
    • tamoxifen
  • Studying tozorakimab for long-term safety in patients with chronic obstructive pulmonary disease

    The research study focuses on Tozorakimab’s long-term safety and efficacy in adults over 40 with frequent COPD flare-ups. It aims to evaluate the time until the first severe flare-up post-treatment, comparing it with the effects of current COPD treatments. The study also assesses Tozorakimab’s additional benefits alongside standard care and monitors participants’ blood for drug levels and physiological reactions. This research is key in developing improved management strategies for COPD.

    • Tozorakimab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • Alteplase low-dose trial for acute pulmonary embolism care

    In this trial, participants with a specific type of lung clot called intermediate-high-risk acute pulmonary embolism are given a lower dose of Alteplase, a medication that dissolves blood clots. The study compares the effects of this reduced dose to a non-active placebo to see if it can reduce clot-related risks without increasing bleeding, especially in the brain. The treatment involves a short intravenous injection and is tested alongside standard anticoagulants. Success is measured by patient health 30 days after the treatment, with an eye on long-term outcomes like survival and heart function up to two years later.

    • Alteplase

See more clinical trials in other cities in Spain:

.